US EditionPublished • loading... • Updated
Novo Chops Wegovy Prices, but Doctors Still See Affordability Challenges for Patients
Novo Nordisk cuts self-pay prices on Wegovy and Ozempic with a $199 monthly introductory offer for two months, targeting cash-paying patients amid rising competition.
- Novo Nordisk has reduced prices for its weight loss drug Wegovy and diabetes drug Ozempic to improve accessibility, according to a company announcement.
- The cash-pay cost for the highest dose of Ozempic remains at $499 per month, according to Novo Nordisk.
- New cash-paying patients can access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months.
- This pricing strategy follows President Donald Trump's agreements with Novo Nordisk and Eli Lilly to enhance accessibility to these drugs for Americans.
Insights by Ground AI
Podcasts & Opinions
111 Articles
111 Articles
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Key PointsPfizer's CEO thinks his company will make big waves in the weight loss market.Eli Lilly does have a strong hold on the industry and won't let go anytime soon.Even so, Lilly could carve out a niche in this and other areas, and eventually bounce back.10 stocks we like better than Pfizer › Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predi…
·Alexandria, United States
Read Full Article
Waterloo Cedar Falls Courier+6 Reposted by 6 other sources
GLP-1 drug prices to dip
President Donald Trump unveiled a deal this month with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.
·Waterloo, United States
Read Full ArticleCoverage Details
Total News Sources111
Leaning Left13Leaning Right8Center60Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 16%
C 74%
Factuality
To view factuality data please Upgrade to Premium
